The International Contrast Ultrasound Society (ICUS)

GE Healthcare Receives Approval for Its Own Manufacturing of Optison™

On November 18, 2013, GE Healthcare announced that it received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) in-house. Optison is a contrast agent that may improve the visualization of the left ventricular border ─ an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. As a result of the FDA’s action, GE Healthcare will provide a supply of Optison to the US and European markets from its manufacturing facility in Oslo, Norway, becoming the only contrast media manufacturer to supply its own stock to the US.
 
Click here to see full release

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

Toshiba Medical logo resized

samsung-logo

siemens-new-original

philips-icus-logo

mindray

ICUS Tweets

Detect liver cancer effectively and more cheaply, without harmful radiation imaging or costly MRI eqpt. Read more: https://t.co/pxaHpwtAci
Lose weight while you sleep? Maybe soon! Read more at: https://t.co/TNRlXb4oDa
Follow Bubble Conference 2016 comment at #bubble2016

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS News GE Healthcare Receives Approval for Its Own Manufacturing of Optison™